Single Ascending Dose Study of PRX002 in Healthy Subjects

Summary

This single ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX002 in approximately 40 healthy subjects.

Timeline

Start

2014-03

Primary completion

2014-12

Completion

—

Outcome

Met primary endpoint

release “PRX002 was safe and well-tolerated, meeting the primary objective of the study.” prothena.com ↗

release “PRX002 was safe and well-tolerated in healthy volunteers, meeting the primary objective of the study.” prothena.com ↗

release “PRX002 was generally safe and well-tolerated in healthy volunteers, meeting the primary objective of the study.” prothena.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Prasinezumab	Monoclonal antibody	—	Intravenous

Indications